<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972501</url>
  </required_header>
  <id_info>
    <org_study_id>SOVS2019-070</org_study_id>
    <nct_id>NCT03972501</nct_id>
  </id_info>
  <brief_title>An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)</brief_title>
  <official_title>A Single-center, Vehicle-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZR-MD-001 as Adjunctive Therapy to Conventional Therapeutic Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azura Ophthalmics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azura Ophthalmics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in
      patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SOVS2019-070 is a single-center, single-masked (the individual(s) performing efficacy
      measures will be masked to treatment assignment for the patient(s) they are assessing),
      vehicle-controlled, randomized, parallel group study of AZR-MD-001 ointment and AZR-MD-001
      vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Anticipated">June 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy for MGD: Change from Baseline in meibum gland secretion score (MGS).</measure>
    <time_frame>Day 14 and month 1</time_frame>
    <description>The MGS can range from 0 (highly abnormal) to 45 (Normal).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy for MGD: Change from Baseline in Meibomian Glands Yielding Liquid Secretion (MGYLS).</measure>
    <time_frame>Day 14 and month 1</time_frame>
    <description>The MGS can range from 0 (highly abnormal) to 15 (Normal)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy for CLD: Change from Baseline in meibum gland secretion score (MGS).</measure>
    <time_frame>Day 14 and month 1</time_frame>
    <description>The MGS can range from 0 (highly abnormal) to 45 (Normal).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy for CLD: Change from Baseline in lid-wiper epitheliopathy.</measure>
    <time_frame>Day 14 and month 1</time_frame>
    <description>Endpoint taken from Table 1 in Siddireddy et al (2018) (Optom Vis Sci 2018;95:1035-1045)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy for CLD:Change from Baseline in subjective vision ratings (VAS).</measure>
    <time_frame>Day 14 and month 1</time_frame>
    <description>VAS can range from 0 (highly normal) to 100 (Abnormal).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Meibomian Gland Dysfunction (MGD)</condition>
  <condition>Contact Lens Discomfort (CLD)</condition>
  <arm_group>
    <arm_group_label>AZR-MD-001 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AZR-MD-001 Vehicle will be dosed up to once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZR-MD-001 Active Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZR-MD-001 Active Dose will be dosed up to once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZR-MD-001 Vehicle</intervention_name>
    <description>AZR-MD-001 is an ophthalmic ointment</description>
    <arm_group_label>AZR-MD-001 Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZR-MD-001 Active Dose</intervention_name>
    <description>AZR-MD-001 is an ophthalmic ointment</description>
    <arm_group_label>AZR-MD-001 Active Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MGD Patients:

               -  Evidence of meibomian gland obstruction (based on a meibomian gland secretion
                  (MGS) score of ≤12 for 15 glands of the lower lid) in both eyes at the baseline
                  visit

               -  Reported dry eye signs and symptoms within the past 3 months

               -  TBUT &lt; 10 seconds in both eyes

          -  CLD Patients:

               -  Evidence of meibomian gland obstruction (based on a meibomian gland secretion
                  (MGS) score of ≤12 for 15 glands of the lower lid) in both eyes at the baseline
                  visit

               -  A history of wearing soft contact lenses for at least 6 months

               -  Wearing of the soft contact lenses for at least 3 weeks before the baseline visit
                  and wore or attempted to wear lenses at least 4 times a week before the baseline
                  visit.

               -  Symptomatic as defined by an answer of &quot;No&quot; at baseline to the question, &quot;Are you
                  able to comfortably wear your lenses as long as you want?&quot;

               -  Self-reported history of contact lens dryness/intolerance in the 6 months
                  preceding the baseline visit.

               -  Baseline CLDEQ-8 score &gt;12

               -  Contact lens may be use during the study as long as they are removed 15 minutes
                  before dosing and not reinserted until at least 15 minutes after dosing.

        Exclusion Criteria:

          -  Uncontrolled ocular disease (except for MGD or CLD) or uncontrolled systemic disease

          -  Patient has glaucoma or ocular hypertension

          -  Corneal abnormality or disorder that impacts normal spreading of the tear film or
             corneal integrity

          -  BCVA worse than 20/40 in either eye at the baseline visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles Bosworth, PhD</last_name>
    <phone>7145598435</phone>
    <email>charles.bosworth@azuraophthalmics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Gleeson</last_name>
    <phone>+61 422 956 128</phone>
    <email>admin@azuraophthalmics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>School of Optometry and Vision Science, University of New South Wales</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Tan-Showlin, PhD, BOptom</last_name>
      <phone>+ 61 (02) 9385 6551</phone>
      <email>jacqueline.tan@unsw.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

